Joanna Rhodes1, Anthony Mato2, Jeff P Sharman3. 1. University of Pennsylvania, 3400 Civic Center Blvd, PCAM 12 South, Philadelphia, PA, 19104, USA. Joanna.rhodes@uphs.upenn.edu. 2. Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. 3. Williamette Valley Cancer Institute and Research Center, Eugene, OR, USA.
Abstract
PURPOSE REVIEW: B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of these drugs, their efficacy, and toxicity management. RECENT FINDINGS: Ibrutinib use is associated with increased risk of atrial fibrillation and bleeding which can be managed using dose interruptions and modifications. Patients on idelalisib require close clinical and frequent laboratory monitoring, particularly of liver function tests to ensure there are no serious adverse events. Monitoring for infections is important in patients on both idelalisib and ibrutinib. Venetoclax requires close clinical and laboratory monitoring to prevent significant tumor lysis. Targeted B cell receptor therapies each have unique side effect profiles which require careful clinical monitoring. As we continue to use these therapies, optimal management strategies will continue to be elucidated.
PURPOSE REVIEW: B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of these drugs, their efficacy, and toxicity management. RECENT FINDINGS:Ibrutinib use is associated with increased risk of atrial fibrillation and bleeding which can be managed using dose interruptions and modifications. Patients on idelalisib require close clinical and frequent laboratory monitoring, particularly of liver function tests to ensure there are no serious adverse events. Monitoring for infections is important in patients on both idelalisib and ibrutinib. Venetoclax requires close clinical and laboratory monitoring to prevent significant tumor lysis. Targeted B cell receptor therapies each have unique side effect profiles which require careful clinical monitoring. As we continue to use these therapies, optimal management strategies will continue to be elucidated.
Authors: Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai Journal: J Clin Invest Date: 2007-01 Impact factor: 14.808
Authors: Susan M O'Brien; Nicole Lamanna; Thomas J Kipps; Ian Flinn; Andrew D Zelenetz; Jan A Burger; Michael Keating; Siddhartha Mitra; Leanne Holes; Albert S Yu; David M Johnson; Langdon L Miller; Yeonhee Kim; Roger D Dansey; Ronald L Dubowy; Steven E Coutre Journal: Blood Date: 2015-10-15 Impact factor: 22.113
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Darryl P Leong; François Caron; Christopher Hillis; Annie Duan; Jeff S Healey; Graeme Fraser; Deborah Siegal Journal: Blood Date: 2016-05-31 Impact factor: 22.113
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda Journal: Lancet Oncol Date: 2016-05-10 Impact factor: 41.316
Authors: B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield Journal: Proc Natl Acad Sci U S A Date: 1997-04-29 Impact factor: 11.205
Authors: P Pérez-Galán; G Roué; M López-Guerra; M Nguyen; N Villamor; E Montserrat; G C Shore; E Campo; D Colomer Journal: Leukemia Date: 2008-07-03 Impact factor: 11.528
Authors: Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: K Uminski; K Brown; O Bucher; I Hibbert; D H Dhaliwal; J B Johnston; M Geirnaert; D E Dawe; V Banerji Journal: Curr Oncol Date: 2019-10-01 Impact factor: 3.677
Authors: Lisa S Chen; Prithviraj Bose; Nichole D Cruz; Yongying Jiang; Qi Wu; Philip A Thompson; Shuju Feng; Michael H Kroll; Wei Qiao; Xuelin Huang; Nitin Jain; William G Wierda; Michael J Keating; Varsha Gandhi Journal: Blood Date: 2018-09-25 Impact factor: 25.476